Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Should You Sell?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped down before the market opened on Tuesday . The stock had previously closed at $27.14, but opened at $26.00. Chugai Pharmaceutical shares last traded at $27.05, with a volume of 18,507 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Smbc Nikko Sec. upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. UBS Group upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the stock presently has an average rating of “Strong Buy”.

Chugai Pharmaceutical Trading Up 0.5%

The stock has a market capitalization of $89.29 billion, a P/E ratio of 31.18 and a beta of 0.69. The business’s fifty day simple moving average is $29.18 and its two-hundred day simple moving average is $26.85.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Thursday, January 29th. The company reported $0.25 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. The company had revenue of $2.25 billion for the quarter. On average, equities research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.